Universal screening to age 70 identifies diabetes in most cases
Apr 07, 2023
An age-based screening method (35 to 70) identifies the greatest proportion of adults with prediabetes and diabetes compared with USPSTF recommendations and BMI-based screening, investigators say.
Most US adults with type 2 diabetes meet criteria for GLP-RAs, SGLT2is
Feb 28, 2023
More than 82% US adults with type 2 diabetes meet the criteria to be prescribed the drugs, yet only 9% use either of them.
Analysis: Medication adherence spotty among U.S. diabetes patients
By
Alicia Lasek
Feb 01, 2023
A sizable percentage of patients with diabetes do not consistently take prescribed medications to lower cholesterol, glucose or blood pressure, investigators say.
Diabetes indicators improve with use of health incentives, CDC study finds
By
Alicia Lasek
Nov 10, 2022
Incentivizing patients to follow a lifestyle modification program helps them to improve a full range of diabetes-related health measures, according to a new meta-analysis.
Common diabetes drug may serve as novel Afib treatment
By
Alicia Lasek
Oct 13, 2022
If approved, it would be the first new drug identified to treat this disease of the heart in a decade, according to Cleveland Clinic researchers.
ADA: Diabetes may quadruple risk for long COVID
Jun 08, 2022
Diabetes may increase the risk for long COVID symptoms fourfold, according to research presented at the annual meeting of the American Diabetes Association.
ADA updates standards of medical care in diabetes for 2022
Jan 11, 2022
Updates include recommendation to screen for prediabetes and diabetes in all people starting at age 35 years
Statin initiation linked to greater progression of diabetes
Oct 04, 2021
Each individual component of the composite outcome was significantly higher among statin users
Diabetes drug turned weight loss med spurs cost-benefit concerns for docs
By
Alicia Lasek
Aug 13, 2021
The high price tag and lack of coverage for high-performing anti-obesity drug Wegovy begs the question of what the benefits of weight loss are worth to insurers and patients.
FDA approves first biosimilar insulin product
Jul 29, 2021
Semglee (insulin glargine-yfgn) is biosimilar to and interchangeable with Lantus (insulin glargine), provides cost-effective option